Imagerie cérébrale de la maladie d'Alzheimer: État de l'art et perspectives pour le clinicien

Translated title of the contribution: Brain imaging of Alzheimer' disease: State of the art and perspectives for clinicians

Sara Trombella, Frédéric Assal, Dina Zekry, Gabriel Gold, Panteleimon Giannakopoulos, Valentina Garibotto, Jean François Démonet, Giovanni B. Frisoni

Research output: Contribution to journalReview article

Abstract

To improve the clinical detection of Alzheimer's disease (AD) new diagnostic criteria have been proposed, based on biomarkers of synaptic dysfunction, AD-related neurodegeneration, and Ab cerebral amyloidosis. Magnetic resonance imaging (MRI) and position emission tomography (PET) neuroimaging can be configured as powerful means for the detection of medial-temporal atrophy, reduced uptake of 18F-FDG PET or and increased retention of Ab amyloid protein by amyloïd-PET. In this review, we will discuss these promising techniques that allow assessing in vivo AD pathology and help clinicians to better diagnose and follow-up patients, particularly in clinical trials using disease-modifying treatments.

Translated title of the contributionBrain imaging of Alzheimer' disease: State of the art and perspectives for clinicians
Original languageFrench
Pages (from-to)795-798
Number of pages4
JournalRevue Medicale Suisse
Volume12
Issue number515
Publication statusPublished - Apr 20 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Brain imaging of Alzheimer' disease: State of the art and perspectives for clinicians'. Together they form a unique fingerprint.

  • Cite this

    Trombella, S., Assal, F., Zekry, D., Gold, G., Giannakopoulos, P., Garibotto, V., Démonet, J. F., & Frisoni, G. B. (2016). Imagerie cérébrale de la maladie d'Alzheimer: État de l'art et perspectives pour le clinicien. Revue Medicale Suisse, 12(515), 795-798.